Norbrook, the Newry-based company, which is a world leader in veterinary pharmaceuticals, has made clear its intention to remain an independent business at the forefront of that industry. In the aftermath of the tragic death of its founder, Lord Ballyedmond, the company is moving to strengthen its Board and management team.
The Board of Norbrook Holdings has been augmented by the appointment to the Board of Lady Ballyedmond, Professor James Haughey and Mr Edward Haughey. They join the existing board members – Sir Roy McNulty and Martin Murdock.
Sir Roy, who has been associated with Norbrook for many years as an adviser and Board member, has been appointed Chairman and Lady Ballyedmond as Deputy Chair. It is the company’s intention to further strengthen the Board over the next year or two through the appointment of additional non-executive members.
The company plans to strengthen its management team through the appointment of a Chief Executive and a Director of Global Sales & Marketing. The recruitment process for these positions is already underway.
Pending appointment of the Chief Executive, day-to-day executive leadership of Norbrook is in the hands of its Management Committee, chaired by Dr Lilian Cromie. The other Management Committee members are Martin Murdock, Derek Rodgers, Lady Ballyedmond, James Haughey and Edward Haughey.
Commenting on the way forward for the company, Lady Ballyedmond said:
“It is our intention that Norbrook will remain under the control of the family as an independent company within the veterinary pharmaceutical industry. It is also our intention that the company’s headquarters and its main R&D and manufacturing operations will continue to be located in Newry.”
Sir Roy McNulty said:
“I am honoured to have been appointed as Chairman of Norbrook. The company has every prospect of a very bright future through building on the strong foundations laid by Lord Ballyedmond over the past 45 years. There are many exciting opportunities ahead of Norbrook and it will be our aim to continue on the path of profitable innovation-led growth which the company has followed since its inception.”
